Trial Profile
An expanded access protocol of Imatinib Mesylate in patients with either chronic myeloid leukemia in accelerated phase or Philadelphia chromosome-positive acute lymphoblastic leukemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 25 Sep 2005 New trial record.